(2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversibleCa_v3.2 T-type Ca²⁺channels (T-channels)blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice^[1].

(2R/S)-6-PNG (6-Prenylnaringenin) potently blocks Ca_v3.2, but exhibits minor effect on high-voltage-activated Ca²⁺channels and voltage-gated Na⁺channels in differentiated NG108-15 cells^[1].
On the basis of IC50 values, the proportion (Ca_v3.2/HVA) of the inhibition potency of (2R/S)-6-PNG on Ca_v3.2 and HVA-currents is 5.20, and that (Ca_v3.2/Na_v) on Ca_v3.2 and Na_v-currents is 3.54^[1].

(2R/S)-6-PNG (6-Prenylnaringenin; 10-30 mg/kg; i.p.; single dose; 15 min before Na2S) significantly reduced the Na₂S-induced nociceptive behavior and/or referred hyperalgesia in onscious mice with intracolonic (i.col.) administration of Na₂S, an H₂S donor^[1].
(2R/S)-6-PNG (30 mg/kg; i.p.) prevents the increased number of phosphorylated ERK-positive cells following i.col. Na2S in laminae I-II, V-VI and X to which the primary afferent neurons project, and the Na2S-induced increase in the phosphorylated ERK-positive cell number^[1].
(2R/S)-6-PNG (0.01-1 and 0.1-10 nmol/paw; intraplantar administration) restores the mechanical allodynia induced by partial sciatic nerve ligation (PSNL) and by i.p. administration of Oxaliplatin (OHP) a, respectively, in a dose-dependent manner^[1].
(2R/S)-6-PNG (20-30 mg/kg; i.p.) significantly reverses the PSNL-induced allodynia. (2R/S)-6-PNG (10-20 mg/kg; i.p.) significantly reverses the OHP-induced allodynia (5 mg/kg; i.p.; single dose)^[1].

340.37

Solid

C₂₀H₂₀O₅

68682-01-9

Room temperature in continental US; may vary elsewhere.

DMSO : 125 mg/mL(367.25 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 10% DMSO    40%PEG300   5%Tween-80   45% saline

  Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

  将 0.9 g 氯化钠，完全溶解于 100 mL ddH2O 中，得到澄清透明的生理盐水溶液
• 2.

  请依序添加每种溶剂： 10% DMSO    90% (20%SBE-β-CDin saline)

  Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

  将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
• 3.

  请依序添加每种溶剂： 10% DMSO    90%corn oil

  Solubility: ≥ 2.08 mg/mL (6.11 mM); Clear solution

  此方案可获得 ≥ 2.08 mg/mL (6.11 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

  以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。